Anuh Pharma Ltd
Anuh Pharma Q1 FY26: Revenue ₹186.48 Cr, PAT ₹8.30 Cr
Q1 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹186Cr
- +34.8% YoY
- Net profit
- ₹8Cr
- −20% YoY
- Margin
- 6%
- −2 pp YoY
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Anuh Pharma Ltd Q1 FY26 key numbers
- Revenue
- Total Revenue (last 5 years): ₹671 Cr for FY 24-25, showing steady growth.
As stated in Anuh Pharma Ltd's Q1 FY26 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Anuh Pharma Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Operating Revenue for Q1 FY 2026: ₹186.48 Cr, a 35.22% increase year-on-year from ₹137.91 Cr in Q1 FY 2025. EBITDA for Q1 FY26: ₹13.68 Cr.
From Anuh Pharma Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Operating Revenue for Q1 FY 2026: ₹186.48 Cr, a 35.22% increase year-on-year from ₹137.91 Cr in Q1 FY 2025. (Page 13, 6)
- Export Sales and Domestic Sales for Q1 FY 2026: Export 36%, Domestic 55% of revenue; for Q1 FY 2025: Export 36%, Domestic 32%. (Page 9)
- Total Revenue (last 5 years): ₹671 Cr for FY 24-25, showing steady growth. (Page 8)
- Future Outlook: Anticipates a steady growth rate of 15-16% per annum, driven by market expansion, new products, and inorganic growth opportunities. (Page 34)
2 more points from Anuh Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Anuh Pharma Ltd said on order book & pipeline — free account, 30 seconds.
Anuh Pharma Ltd — Quarterly revenue & net profit
Anuh Pharma Ltd Q1 FY26 results — key figures
| ₹ Cr | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 186 | 138 | +34.8% | 198 | -6.1% |
| Operating profit (EBITDA) | 10 | 11 | -9.1% | 19 | -47.4% |
| Operating margin | 6% | 8% | -2 pp | 9% | -3 pp |
| Profit before tax | 11 | 12 | -8.3% | 17 | -35.3% |
| Net profit (PAT) | 8 | 10 | -20% | 12 | -33.3% |
| EPS (₹) | 0.83 | 0.95 | -12.6% | 1.24 | -33.1% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹185 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anuh Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Anuh Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anuh Pharma Ltd Q1 FY26 results?
Operating Revenue for Q1 FY 2026: ₹186.48 Cr, a 35.22% increase year-on-year from ₹137.91 Cr in Q1 FY 2025. EBITDA for Q1 FY26: ₹13.68 Cr.
What is Anuh Pharma Ltd share price analysis?
Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.